Inari Medical, Inc. (NASDAQ:NARI) Director Sells $3,069,600.00 in Stock

Inari Medical, Inc. (NASDAQ:NARI) Director William Hoffman sold 60,000 shares of the stock in a transaction dated Monday, November 18th. The shares were sold at an average price of $51.16, for a total transaction of $3,069,600.00. Following the completion of the sale, the director now directly owns 501,233 shares in the company, valued at approximately $25,643,080.28. The trade was a 10.69 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

William Hoffman also recently made the following trade(s):

• On Tuesday, October 29th, William Hoffman sold 40,000 shares of Inari Medical stock. The shares were sold at an average price of $50.05, for a total transaction of $2,002,000.00.
• On Wednesday, October 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.02, for a total transaction of $1,800,800.00.
• On Monday, September 16th, William Hoffman sold 40,000 shares of Inari Medical stock. The stock was sold at an average price of $45.83, for a total value of $1,833,200.00.

Inari Medical Trading Down 0.2 %

Shares of NARI opened at $49.66 on Friday. Inari Medical, Inc. has a twelve month low of $36.73 and a twelve month high of $67.13. The firm has a market capitalization of $2.91 billion, a P/E ratio of -36.78 and a beta of 0.96. The stock’s fifty day simple moving average is $45.60 and its 200 day simple moving average is $47.21.

Hedge Funds Weigh In On Inari Medical

A number of large investors have recently modified their holdings of NARI. GAMMA Investing LLC increased its position in Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock worth $34,000 after purchasing an additional 438 shares in the last quarter. Nisa Investment Advisors LLC increased its position in shares of Inari Medical by 83.5% in the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after acquiring an additional 435 shares in the last quarter. KBC Group NV increased its position in shares of Inari Medical by 39.0% in the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after acquiring an additional 498 shares in the last quarter. Covestor Ltd raised its stake in shares of Inari Medical by 30.2% in the 1st quarter. Covestor Ltd now owns 1,619 shares of the company’s stock valued at $78,000 after acquiring an additional 376 shares during the period. Finally, Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Inari Medical by 39.4% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock valued at $89,000 after acquiring an additional 522 shares in the last quarter. 90.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Leerink Partners began coverage on shares of Inari Medical in a research note on Tuesday, September 3rd. They set a “market perform” rating and a $47.00 price target on the stock. Wells Fargo & Company decreased their target price on shares of Inari Medical from $84.00 to $65.00 and set an “overweight” rating on the stock in a research report on Wednesday, July 31st. Piper Sandler lifted their target price on shares of Inari Medical from $50.00 to $52.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 29th. Truist Financial increased their price target on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research note on Tuesday, October 29th. Finally, Deutsche Bank Aktiengesellschaft assumed coverage on Inari Medical in a research report on Friday, August 9th. They issued a “buy” rating and a $68.00 price objective for the company. Six equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. According to MarketBeat.com, Inari Medical presently has an average rating of “Hold” and a consensus price target of $58.89.

About Inari Medical

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.